Loading...
XNAS
CSII
Market cap1.44bUSD
Apr 27, Last price  
20.00USD
Name

Cardiovascular Systems Inc

Chart & Performance

D1W1MN
XNAS:CSII chart
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
—
Rev. gr., 5y
4.51%
Revenues
236m
-8.79%
0726,000834,000441,00015,988,00058,571,00056,461,00064,829,00078,780,00082,490,000103,897,000136,612,000181,544,000178,184,000204,906,000217,043,000248,017,000236,545,000258,973,000236,222,000
Net income
-37m
L+175.19%
-3,762,000-13,950,000-19,239,000-33,669,000-29,249,0007,692,000-9,114,000-23,904,000-11,125,000-16,790,000-24,037,000-35,290,000-32,822,000-56,024,000-1,792,0001,712,000-255,000-27,236,000-13,421,000-36,933,000
CFO
-24m
L+2,645.70%
-17,186,000-26,459,00022,172,000-34,715,000-29,710,000-13,566,000-8,361,000-11,340,000-10,765,000-26,838,000-22,357,000-23,583,00019,588,0009,674,00010,208,000-12,765,000-884,000-24,272,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Cardiovascular Systems, Inc., a medical technology company, develops and commercializes solutions to treat peripheral and coronary artery diseases in the United States and internationally. The company offers peripheral artery disease products comprising catheter-based platforms to treat various plaque types in above and below the knee, including calcified plaque, as well as address various limitations related with surgical, catheter, and pharmacological treatment alternatives; and peripheral support products. It also provides Diamondback 360 Coronary orbital atherectomy systems (OAS), a coronary artery disease (CAD) product designed to facilitate stent delivery in patients with CAD who are acceptable candidates for percutaneous transluminal coronary angioplasty or stenting due to severely calcified coronary artery lesions. In addition, it offers guidewires, catheters, balloons, embolic protection system, and other OAS support products. Cardiovascular Systems, Inc. has a partnership with Chansu Vascular Technologies, LLC to develop novel peripheral and coronary everolimus drug-coated balloons. The company was formerly known as Shturman Cardiology Systems, Inc. and changed its name to Cardiovascular Systems, Inc. in January 2003. Cardiovascular Systems, Inc. was founded in 1989 and is headquartered in Saint Paul, Minnesota.
URL
https://csi360.com/
IPO date
Jun 28, 2006
Employees
725
Domiciled in
US
Incorporated in
US

Valuation

Title
in thousands, except ratios and share amounts
FYFYFYFYFYFYFY
2022‑062021‑062020‑062019‑062018‑062017‑062016‑06
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT